Funding Rounds
IntraBio

IntraBio Series B (2024, $40M)

IntraBio

New drug application (NDA) IB1001 developer for the treatment of Niemann-pick disease type C (NPC).

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $40.27M